Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

BOEHRINGER, LILLY START TRAJENTA MARLINAT CLINICAL TRIAL (ENG)


(The following press release from Boehringer Ingelheim was received by e-mail. It was not confirmed by the sender.)

Dear Sir/Madam,

Enclosed you will find our latest press release

For Non-U.S. and Non-U.K. Media

Boehringer Ingelheim and Lilly initiate MARLINA(tm) clinical trial to evaluate use of Trajenta® (linagliptin) in patients with type 2 diabetes and albuminuria

which can be accessed at:

http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/19_ma rch_2013_linagliptin.html

All interested users with a web-enabled mobile phone, iPhone, Blackberry, PDA or other mobile device now have fast access to selected, up-to-the-minute information about Boehringer Ingelheim. Just follow: http://mobile.boehringer-ingelheim.com/

Mit freundlichen Grüßen / Kind regards, Arnd Prilipp

Boehringer Ingelheim GmbH Launch + establ. Products CVM Tel.: +49 (6132) 77-2091 Fax: +49 (6132) 77-6601 mailto:press@boehringer-ingelheim.com

Visit us... <http://www.boehringer-ingelheim.com/> <<Picture (Device Independent Bitmap)>> <http://www.facebook.com/boehringeringelheim> <<Picture (Device Independent Bitmap)>> <http://www.twitter.com/boehringer> <<Picture (Device Independent Bitmap)>> <http://www.youtube.com/boehringeringelheim> <<Picture (Device Independent Bitmap)>> <http://www.flickr.com/photos/125yearsmorehealth/> <<Picture (Device Independent Bitmap)>> Boehringer Ingelheim GmbH, Unternehmensleitung: Prof. Dr. Dr. Andreas Barner (Sprecher), Hubertus von Baumbach, Prof. Dr. Wolfram Carius, Engelbert Tjeenk Willink; Vorsitzender des Aufsichtsrates: Christian Boehringer, Sitz: Ingelheim am Rhein; Registergericht Mainz: HR B 21005

Diese E-Mail ist vertraulich zu behandeln. Sie kann besonderem rechtlichen Schutz unterliegen. Wenn Sie nicht der richtige Adressat sind, senden Sie bitte diese E-Mail an den Absender zurück, löschen die eingegangene E-Mail und geben den Inhalt der E-Mail nicht weiter. Jegliche unbefugte Bearbeitung, Nutzung, Vervielfältigung oder Verbreitung ist verboten. / This e-mail is confidential and may also be legally privileged. If you are not the intended recipient please reply to sender, delete the e-mail and do not disclose its contents to any person. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited.

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement